コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 atients with a response continued to receive eltrombopag.
2 s, resulting in the early discontinuation of eltrombopag.
3 1-2 study of immunosuppressive therapy plus eltrombopag.
4 to splenectomy, rituximab, romiplostim, and eltrombopag.
5 atient assigned to receive placebo was given eltrombopag.
6 LT patients whose platelet count improved on eltrombopag.
7 all patients could receive up to 24 weeks of eltrombopag.
8 median of 13 months (range, 1-15 months) off eltrombopag.
9 ceiving placebo, 10 of 14 receiving 30 mg of eltrombopag, 14 of 19 receiving 50 mg of eltrombopag, an
10 atment, with 45 patients assigned to receive eltrombopag (16 children aged 12-17 years, 19 aged 6-11
11 ar proportions had MDS (50 [51%] patients to eltrombopag, 22 (47%) patients to placebo) or AML (48 [4
12 Proportionately fewer patients who received eltrombopag (23 [37%] of 63 patients) had WHO grades 1-4
14 millimeter were randomly assigned to receive eltrombopag (30, 50, or 75 mg daily) or placebo daily fo
16 tment received standard care plus once-daily eltrombopag 50 mg (n=76) or placebo (n=38) for up to 6 w
17 cacy, safety, and tolerability of once daily eltrombopag 50 mg, and explored the efficacy of a dose i
18 ents were randomly assigned (2:1) to receive eltrombopag (50 mg to 300 mg) or placebo for at least 24
19 0 mg by mouth, days 1-4) in combination with eltrombopag (50 mg, days 5-32) in 12 adults with newly d
20 rom weeks 5-12 were significantly lower with eltrombopag (54% [95% CI 43-64]) than with placebo (69%
21 avoided in 104 of 145 patients who received eltrombopag (72%) and in 28 of 147 who received placebo
22 ia that was refractory to immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist
23 All 5 patients with a platelet response to Eltrombopag, a thrombopoietic agent, but none responding
25 nd colleagues examine the in vivo effects of eltrombopag, a thrombopoietin receptor agonist (TPO-RA),
28 hat were suspected to be study drug-related (eltrombopag: acute kidney injury, arterial thrombosis, b
29 Orally available, TPO nonpeptide mimetics (eltrombopag, AKR-501) bind and activate the TPO receptor
30 In this study (ASPIRE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, fo
36 ts occurred in five (11%) patients receiving eltrombopag and four (19%) patients receiving placebo, a
37 sessment of long-term safety and efficacy of eltrombopag and its effect on survival (phase 2 part of
41 TION: No new safety concerns were noted with eltrombopag and the trial met the primary objective of a
42 adverse events (four [9%] patients receiving eltrombopag and two (10%) patients receiving placebo) we
44 of eltrombopag, 14 of 19 receiving 50 mg of eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag
46 mbopag, in 15 of 19 (79%) receiving 50 mg of eltrombopag, and in 20 of 21 (95%) receiving 75 mg of el
49 lacebo (13 [42%] of 31 patients) than in the eltrombopag arm (eight [14%] of 59 patients; p=0.0025).
50 tem were observed in 6 patients who received eltrombopag, as compared with 1 who received placebo, re
51 ding phase, patients aged 6-17 years started eltrombopag at 25 mg once per day (12.5 mg for those wei
53 atment period in which all patients received eltrombopag at either the starting dose (if they were fo
54 than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14
56 let reactivity to TRAP only in responders to eltrombopag but not to levels above those in controls; w
59 weeks 1 to 6, 28 (62%) patients who received eltrombopag, compared with seven (32%) who received plac
63 baseline platelet activation than controls, eltrombopag did not cause platelet activation or hyper-r
64 However, two patients assigned to receive eltrombopag did not receive the study drug and one was l
68 m analysis of the ongoing open-label EXTEND (Eltrombopag eXTENded Dosing) study evaluates the safety
69 ed to investigate the safety and efficacy of eltrombopag for children with chronic immune thrombocyto
71 med to assess the safety and tolerability of eltrombopag for the treatment of thrombocytopenia in adu
72 preclinical rationale for further testing of Eltrombopag for treatment of thrombocytopenia in AML and
73 f the eltrombopag regimen (cohort 1 received eltrombopag from day 14 to 6 months, cohort 2 from day 1
74 ations were done in 40 (63%) patients in the eltrombopag group and 17 (50%) patients in the placebo g
77 er were reported in six (9%) patients in the eltrombopag group and four (12%) patients in the placebo
78 adverse events were fatigue (six [6%] in the eltrombopag group and one [2%] in the placebo group), hy
79 ccurred in seven (12%) of 59 patients in the eltrombopag group versus five (16%) of 31 patients in th
80 s occurred in 27 (46%) of 59 patients in the eltrombopag group versus nine events in five (16%) of 31
81 s occurred in 28 (47%) of 59 patients in the eltrombopag group versus one (3%) of 31 patients in the
82 cause of adverse events: two patients in the eltrombopag group withdrew because of increased liver am
87 t production in WAS/XLT is less than in ITP, eltrombopag has beneficial effects on platelet count but
90 thrombopoietic agents including AMG 531 and eltrombopag have shown promise in the treatment of throm
93 y evaluated long-term safety and efficacy of eltrombopag in adults with ITP who had completed a previ
94 The majority of patients who remained on eltrombopag in an extension study (14/17) continued to s
95 ed to investigate the efficacy and safety of eltrombopag in children with persistent or chronic immun
96 ined standard immunosuppressive therapy with eltrombopag in previously untreated patients with severe
100 placebo, in 9 of 12 (75%) receiving 30 mg of eltrombopag, in 15 of 19 (79%) receiving 50 mg of eltrom
101 , developed new cytogenetic abnormalities on eltrombopag, including 5 with chromosome 7 loss or parti
102 rombopag were dose dependent and linear, and eltrombopag increased platelet counts in a dose-dependen
105 microthrombocytopenia; and (2) although the eltrombopag-induced increase in platelet production in W
113 The oral thrombopoietin receptor agonist eltrombopag is approved for treatment of adults with chr
118 e primary objective of a reduction in CRTEs; eltrombopag might be a treatment option for thrombocytop
120 145 patients to receive supportive care plus eltrombopag (n=98) or placebo (n=47); similar proportion
122 In this work, we studied the effects of Eltrombopag on proliferation, apoptosis, differentiation
123 (block size of three), to receive once-daily eltrombopag or matching placebo dose adjusted from 50 mg
124 ed supportive standard of care and initiated eltrombopag or placebo at 100 mg per day (50 mg per day
126 nd randomly assigned (2:1) to receive either eltrombopag or placebo tablets (or oral suspension formu
128 sing an interactive voice-response system to eltrombopag or placebo, stratified by baseline platelet
129 ntiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and
133 nts were randomly assigned in a 2:1 ratio of eltrombopag:placebo by a validated randomisation system.
140 timing of initiation and the duration of the eltrombopag regimen (cohort 1 received eltrombopag from
141 atients receiving 30 mg, 50 mg, and 75 mg of eltrombopag, respectively, and by 6% of patients in the
146 se events that occurred more frequently with eltrombopag than with placebo included nasopharyngitis (
148 rse events leading to study discontinuation (eltrombopag, three [4%]; placebo, two [5%]), were simila
150 ous adverse events were reported in 56 (58%) eltrombopag-treated patients and 32 (68%) placebo-treate
155 he 302 patients enrolled, median duration of eltrombopag treatment was 2.37 years (2 days-8.76 years)
157 ithout added agonist was unchanged following eltrombopag treatment, whereas a slight increase in P-se
158 f grade 3-4 adverse events during treatment (eltrombopag, two [3%]; placebo, one [3%]) and adverse ev
159 g were headache (13 [30%] patients receiving eltrombopag vs nine [43%] patients receiving placebo), u
161 re similar (three [5%] patients who received eltrombopag vs two [7%] patients who received placebo).
162 clinical trial in 73 healthy male subjects, eltrombopag was administered as once-daily oral capsules
165 EXTEND demonstrated that long-term use of eltrombopag was effective in maintaining platelet counts
167 or the groups receiving 30, 50, and 75 mg of eltrombopag were 26,000, 128,000, and 183,000 per cubic
171 eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag) while the administration of eltrombopag or
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。